U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06375187) titled 'A Phase I Study on Engineering Tumor Infiltrating Lymphocytes Injection (GC203 TIL) for the Treatment of Advanced Malignant Solid Tumors' on April 16.
Brief Summary: A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors
Study Type: Interventional
Condition: * Solid Tumor
* Gynecologic Cancer
* Breast Cancer
* Gastrointestinal Cancer
* Lung Cancer
Intervention: Biological: Engineering Tumor Infiltrating Lymphocytes
A tumor sample is resected from each participant and cultured ex vivo to generate the engineered tumor infiltrat...